Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 5, 2007, Pages 669-675

  Chen, Tsung Ming ^a   Huang, Pi Teh ^a   Tsai, Ming Hung ^a   Lin, Lien Fu ^a   Liu, Chung Cheng ^a   Ho, Ka Sic ^a   Siauw, Chuan Pau ^a   Chao, Po Liang ^a   Tung, Jai Nien ^a  

^a TUNGS' TAICHUNG METROHARBOR HOSPITAL   (Taiwan)

Author keywords

Alpha fetoprotein; Hepatitis C virus; Hepatocellular carcinoma; Interferon

Indexed keywords

ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONFIDENCE INTERVAL; CONTROLLED STUDY; ERADICATION THERAPY; FEMALE; FIBROSIS; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK; SENESCENCE; THROMBOCYTE COUNT;

EID: 34247214966     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2007.04898.x     Document Type: Article

References (29)

1. Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999; 29: 1311-16.
2. Fattovich G, Giustina G, Degos F et al. Morbidity and mortality in compensated cirrhosis type C. a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-72.
3. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002; 36 (Suppl. 1): S74-83.
4. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-136.
5. Gupta S, Bent S, Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann. Intern. Med. 2003; 139: 46-50.
6. Takikawa Y, Suzuki K. Is AFP a new reliable marker of liver regeneration in acute hepatic failure? J. Gastroenterol. 2002; 37: 681-2.
7. Liaw YF, Tai DI, Chen TJ et al. Alpha-fetoprotein changes in the course of chronic hepatitis: relation to bridging hepatic necrosis and hepatocellular carcinoma. Liver 1986; 6: 133-7.
8. Chu CW, Hwang SJ, Luo JC et al. Clinical, virologic, and pathologic significance of elevated serum alpha-fetoprotein levels in patients with chronic hepatitis C. J. Clin. Gastroenterol. 2001; 32: 240-4.
9. Hu KQ, Kyulo NL, Lim N et al. Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. Am. J. Gastroenterol. 2004; 99: 860-5.
10. Di Bisceglie AM, Sterling RK, Chung RT et al. (HALT-C Trial Group) Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J. Hepatol. 2005; 43: 434-41.
11. Sato Y, Nakata K, Kato Y et al. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N. Engl. J. Med. 1993; 24: 1802-6.
12. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002; 26: 975-82.
13. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 22: 958-65.
14. Lee SD, Yu ML, Cheng PN et al. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. J. Viral. Hepat. 2005; 12: 283-91.
15. Murashima S, Tanaka M, Haramaki M et al. A decrease in AFP level related to administration of interferon in patients with chronic hepatitis C and a high level of AFP. Dig. Dis. Sci. 2006; 51: 808-12.
16. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20 (1 Pt 1): 15-20.
17. McHutchison JG, Manns M, Patel K et al., International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-9.
18. Hung CH, Lee CM, Lu SN et al. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. J. Viral. Hepat. 2006; 13: 409-14.
19. Fattovich G, Stroffolini T, Zagni I et al. Cirrhosis and hepatocellular carcinoma: incidence and factors related to development of hepatocellular carcinoma. Gastroenterology 2004; 127 (Suppl. 1): S35-50.
20. Taniguchi H, Iwasaki Y, Fujiwara A et al. Long-term monitoring of platelet count, as a non-invasive marker of hepatic fibrosis progression and/or regression in patients with chronic hepatitis C after interferon therapy. J. Gastroenterol. Hepatol. 2006; 21 (1 Pt 2): 281-7.
21. Velazquez RF, Rodriguez M, Navascues CA et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 2003; 37: 520-7.
22. Madhotra R, Mulcahy HE, Willner I et al. Prediction of esophageal varices in patients with cirrhosis. J. Clin. Gastroenterol. 2002; 34: 81-5.
23. Ono E, Shiratori Y, Okudaira T et al. Platelet count reflects stage of chronic hepatitis C. Hepatol. Res. 1999; 15: 192-200.
24. Forns X, Ampurdanes S, Llovet JM et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36 (4 Pt 1): 986-92.
25. Wai CT, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
26. Lu SN, Wang JH, Liu SL et al. Thrombocytopenia as a surrogate of liver fibrosis and a marker of identification of the high risk subjects of hepatocellular carcinoma. Cancer 2006; 107: 2212-22.
27. Yoshida T, Hanada T, Tokuhisa T et al. Activation of STAT3 by the hepatitis C virus core protein leads to cellular transformation. J. Exp. Med. 2002; 196: 641-53.
28. Yano H, Iemura A, Haramaki M et al. Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines. Hepatology 1999; 29: 1708-17.
29. Yoshida H, Tateishi R, Arakawa Y et al. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut 2004; 53: 425-30.